Surgical Decision-Making for Stage I–III Malignant Melanoma: Key Considerations

Surgery is the cornerstone of treatment for localized (Stage I–II) and regional (Stage III) melanoma. Decision-making integrates tumor biology, patient factors, and multidisciplinary expertise.

1. Tumor Stage and Microstaging

  • Breslow thickness: Primary determinant of T stage and margin width (0.5–1 cm ≤1 mm; 1–2 cm 1.01–2 mm; 2 cm >2 mm).
  • Ulceration: Upstages T category; worsens prognosis.
  • Mitotic rate (≥1/mm²): Upstages T1b; adverse prognostic factor.
  • Satellite/in-transit metastases: Stage III; may alter surgical approach.

2. Patient Factors

  • Age, performance status, comorbidities (cardiopulmonary, immune), wound healing capacity.
  • Genetic syndromes (CDKN2A, BRCA2) may influence field cancerization risk.

3. Surgical Margins

  • NCCN guidelines: Clinical margins based on Breslow depth (see above).
  • Peripheral and deep margins must be histologically negative.
  • Mohs or staged excision for cosmetically/ functionally critical sites (face, digits, genitalia).

4. Sentinel Lymph Node Biopsy (SLNB)

  • Indicated for T1b (≥0.8 mm or ulcerated) through T4.
  • Identifies occult nodal disease; guides adjuvant therapy decisions.
  • Positive SLNB → completion lymph node dissection (CLND) or observation (MSLT-II trial) + systemic therapy consideration.

5. Reconstruction and Functional/Cosmetic Outcomes

  • Primary closure, skin graft, local flap, free flap based on defect size/location.
  • Preserve neurovascular structures; minimize lymphedema risk (especially groin/axilla).

6. Multidisciplinary Tumor Board

Surgeon, medical oncologist, radiation oncologist, dermatologist, pathologist, radiologist, genetics counselor review staging, molecular profiling (BRAF, NRAS, NF1), adjuvant options (immunotherapy, targeted therapy), and surveillance plan.

7. Adjuvant Therapy Integration

  • Stage III (resected): Anti-PD-1 (pembrolizumab, nivolumab) or BRAF/MEK inhibitors (if BRAF V600+) per KEYNOTE-054, CheckMate 238, COMBI-AD.
  • Stage IIB/IIC: Pembrolizumab approved (KEYNOTE-716).

Individualized surgical planning within a multidisciplinary framework optimizes oncologic control and quality of life.

Tumors - Related Articles